Floatz logo

Metformin

Insulin Sensitivity/Resistance

Cairo UniversitySmall moleculeEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Insulin Sensitivity/Resistance cohort.

Asset / SponsorPhaseRating
Semaglutide
Nordsjaellands Hospital
Phase 3B
Vericiguat
University of Alabama at Birmingham
Phase 2CCC
Letrozole
Cairo University
Early Phase 1C
Maltodextrin
Virginia Polytechnic Institute and State University
N/AD
Humulin R
University of Copenhagen
N/AD
Sucralose
Virginia Polytechnic Institute and State University
N/AD

Same molecule, other indications

Metformin is also rated in:

Metabolism and Nutrition DisorderDormant
A
Indicative ·
82 / 100
View asset →
prediabetes syndromeDormant
A
Indicative ·
81 / 100
View asset →
gestational diabetesDormant
A
Indicative ·
81 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →